SCHEMBL2860620

SCHEMBL2860620

NC(=O)c1cc(Oc2ccc(NC(=O)C(Cl)(Cl)Cl)c(F)c2)ccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 2/20 0.50
▸ ABL1 P00519 2/20 0.49
▸ MAPK14 Q16539 10/20 0.48
▸ KDR P35968 6/20 0.48
▸ BRAF P15056 5/20 0.48
▸ RIPK2 O43353 2/20 0.48
▸ ABCB11 O95342 1/20 0.48
▸ NR3C1 P04150 1/20 0.48
▸ RET P07949 1/20 0.48
▸ HTR1A P08908 1/20 0.48
▸ PDGFRB P09619 1/20 0.48
▸ ADORA3 P0DMS8 1/20 0.48
▸ KIT P10721 1/20 0.48
▸ CHRM1 P11229 1/20 0.48
▸ BCR P11274 1/20 0.48
▸ FGFR1 P11362 1/20 0.48
▸ RARG P13631 1/20 0.48
▸ PDGFRA P16234 1/20 0.48
▸ FLT1 P17948 1/20 0.48
▸ MAOA P21397 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2851866 0.90 RAF1 (0.51) RAF1ABL1MAPK14KDRBRAF
SCHEMBL1137179 0.89 ABL1 (0.54) RAF1ABL1MAPK14KDRBRAF
SCHEMBL2855928 0.86 MAPK14 (0.62) RAF1ABL1MAPK14KDRBRAF
SCHEMBL2865557 0.82 ABL1 (0.52) RAF1ABL1MAPK14KDRBRAF
SCHEMBL1660418 0.81 MAPK14 (0.54) RAF1ABL1MAPK14KDRBRAF
SCHEMBL1660260 0.80 MAPK14 (0.60) RAF1ABL1MAPK14KDRBRAF
SCHEMBL1662217 0.79 BRAF (0.68) MAPK14KDRBRAF
SCHEMBL1662209 0.79 BRAF (0.69) RAF1ABL1MAPK14KDRBRAF
SCHEMBL1659070 0.78 MAPK14 (0.53) RAF1ABL1MAPK14KDRBRAF
SCHEMBL3561475 0.78 RAF1 (0.47) RAF1ABL1MAPK14KDRBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311972-A1 METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-09 — — US disclosed
US-20100311972-A1 METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-09 — — US disclosed
US-20100311972-A1 METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-09 — — US disclosed
EP-2248810-A1 METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2010-11-10 — — EP disclosed
WO-2009104520-A1 METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) 2009-08-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311972-A1 METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE TET2, QDPR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 RAF1 1892/4885ABL1 51/4885MAPK14 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback